How is NAIT diagnosed?

A diagnosis of NAIT is made by testing the blood of both parents and confirming a suspected diagnosis with fetal or neonatal blood. If a platelet antigen incompatibility exists in the couple, screening for maternal anti-HPA antibodies specific for paternal or neonatal platelet antigens should be performed.

What is NAIT in pregnancy?

Summary. Listen. Fetal and neonatal alloimmune thrombocytopenia (NAIT) is a blood disorder that affects pregnant women and their babies. NAIT was first reported in the literature in 1953 and is estimated to occur in as many as 1 in 1200 live births.

What is HPA 1a?

Platelet specific antigen negative platelets (HPA-1a negative platelets) is used for alloimmune thrombocytopenia and neonatal alloimmune thrombocytopenia (NAIT). Platelet specific antigen negative platelets (HPA-1a negative platelets) is available under the following different brand names: N/A.

When do platelet antigens arise in PAIG antibodies?

Alloimmune platelet-associated immunoglobulin (PAIg) antibodies arise when there is an antigenic challenge to individuals who lack specific platelet antigens. Neonatal alloimmune thrombocytopenia is a serious, potentially fatal disease affecting fetuses and neonates.

Can a platelet antibody be an autoimmune antibody?

Platelet antibodies can be autoimmune (directed against endogenous, i.e., the patient’s own platelet antigens) or alloimmune (directed against antigens on exogenous platelets encountered through pregnancy or transfusion).

When do you get platelet alloantintidies during pregnancy?

Platelet membrane specific antigens are present in the fetus at 18 weeks’ gestation; therefore, cordocentesis commonly is initiated in mothers with human platelet antigen–1b (HPA-1b) with platelet alloantibodies at 20 weeks’ gestation. Continued monitoring and treatment for NAIT is quite controversial.

What to know about immune thrombocytopenia during pregnancy?

Medical Care. [16] IgG antiplatelet antibodies are transmitted through the breast milk, so consider monitoring the platelet counts in breastfed newborns of mothers with ITP. The major neonatal concern in ITP is the risk of fetal or newborn intracranial or visceral hemorrhage due to severe thrombocytopenia.